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OBJECTIVE—To evaluate the extent of pancreatic -cell func-
tion in a large number of insulin-dependent diabetic patients with
a disease duration of 50 years or longer (Medalists).
RESEARCH DESIGN AND METHODS—Characterization of
clinical and biochemical parameters and -cell function of 411
Medalists with correlation with postmortem morphologic ﬁnd-
ings of 9 Medalists.
RESULTS—The Medalist cohort, with a mean  SD disease
duration and age of 56.2  5.8 and 67.2  7.5 years, respectively,
has a clinical phenotype similar to type 1 diabetes (type 1
diabetes): mean  SD onset at 11.0  6.4 years, BMI at 26.0  5.1
kg/m
2, insulin dose of 0.46  0.2 u/kg, 94% positive for DR3
and/or DR4, and 29.5% positive for either IA2 or glutamic acid
decarboxylase (GAD) autoantibodies. Random serum C-peptide
levels showed that more than 67.4% of the participants had levels
in the minimal (0.03–0.2 nmol/l) or sustained range (0.2 nmol/
l). Parameters associated with higher random C-peptide were
lower hemoglobin A1C, older age of onset, higher frequency of
HLA DR3 genotype, and responsiveness to a mixed-meal toler-
ance test (MMTT). Over half of the Medalists with fasting
C-peptide 0.17 nmol/l responded in MMTT by a twofold or
greater rise over the course of the test compared to fasting.
Postmortem examination of pancreases from nine Medalists
showed that all had insulin -cells with some positive for
TUNEL staining, indicating apoptosis.
CONCLUSIONS—Demonstration of persistence and function of
insulin-producing pancreatic cells suggests the possibility of a
steady state of turnover in which stimuli to enhance endogenous
 cells could be a viable therapeutic approach in a signiﬁcant
number of patients with type 1 diabetes, even for those with
chronic duration. Diabetes 59:2846–2853, 2010
T
he incidence of type 1 diabetes is increasing
around the world and age at onset is becoming
younger (1–4). More than 90% of diabetic pa-
tients will develop signiﬁcant vascular complica-
tions resulting in loss of visual acuity, kidney failure, and
increased risk of cardiovascular diseases (5–7). Enhancing
endogenous insulin production in diabetic patients can
substantially improve glycemic control and decrease com-
plications. However, the comparative analysis of residual
pancreatic function and morphology in long-term diabetic
patients has not been studied. The Joslin 50-Year Medalist
Study has been characterizing as a large cohort of patients
who have been insulin dependent for 50 years or longer
(8,9). Surprisingly, preliminary screening by random se-
rum C-peptide levels suggests that a majority of Medalists
may still be producing insulin.
Studies on individuals with extreme duration of type 1
diabetes are rare, but they can be uniquely useful in
identifying protective factors against the development of
complications and for the preservation of endogenous
insulin-producing -cells (10). Bain et al. (8) characterized
the golden years cohort, a population of people with 50 or
more years of type 1 diabetes from the U.K., for compli-
cation status and other clinical parameters, but not for
residual insulin production. Lohr and Kloppel (9) reported
residual -cells in 46% of their 16 autopsied cases of
individuals with more than 21 years duration of diabetes.
Pipeleers and Ling (10) reported residual -cells in 40% of
43 patients with 10–30 years duration of diabetes and
onset after 7 years of age. More recently, Meier et al. (11)
reported the presence of insulin-containing -cells in 88%
of the pancreases from 42 type 1 diabetic patients with
duration of diabetes ranging from 4–67 years of whom 14
had diabetes for 32 or more years. Gianani et al. (12)
reported that 3 of 13 pancreases of people with childhood-
onset diabetes for 10 years or longer were positive for
insulin, but only 1 of these had either DR3 or DR4 allele.
However, no clinical premortem studies on -cell function
were reported in any of these studies.
In the present study, we are reporting the clinical and
physiologic characterization of 411 patients with insulin-
dependent diabetes of 50 years or longer duration, partic-
ularly with regard to their pancreatic -cell function. In
addition, uniquely, multiple samples of pancreases from 9
Medalists were analyzed morphologically and correlated
with premortem data to determine whether the clinical
evidence of residual insulin production correlates with the
pancreatic histologic ﬁndings.
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U.S. residents who received Joslin 50-Year Medals were recruited for partic-
ipation. The Joslin 50-Year Medal is available to any individual who provides
a medical record or three other forms of documentation of 50 or more years
of insulin-dependent diabetes. Information regarding the program is adver-
tised in publications by the American Diabetes Association and the Juvenile
Diabetes Research Foundation, as well as by individual physicians, Medalists,
and the general media. By September 30, 2008, a total of 476 medals had been
awarded to U.S. residents since the beginning of this study, 431 (90.5%)
appointments had been made, and 411 Medalists had completed a study visit.
The reasons for nonparticipation were death in 2 cases, inability to travel/poor
health (8), family member illness (5), and/or work (4). Informed consent was
obtained from all subjects prior to study participation. The Joslin Committee
on Human Subjects approved the study.
Most Medalists (88%) received routine endocrine care outside the Joslin
Diabetes Center. For the data presented here, all study subjects were
evaluated at the Joslin Diabetes Center by medical history, clinical exams, and
blood and urine analysis. Hemoglobin A1C (A1C) was determined by high-
performance liquid chromatography (Tosoh G7 and 2.2, Tokyo, Japan). Lipid
proﬁles were determined by standard enzymatic methods (using kits from
Roche Diagnostics, Indianapolis, IN; Denka Seiken, Tokyo, Japan; and Asa-
hiKasei, Tokyo, Japan). Serum C-peptide was determined by radioimmunoas-
say (Beckman Coulter, Fullerton, CA) and validated at the Northwest Lipid
Research Laboratory at the University of Washington as previously described
(13). The methods of Yu et al. (14) were used at both the Joslin Diabetes
Center and the Barbara Davis Center for Childhood Diseases to assay IA2 and
GAD 65 autoantibodies.
Mixed-meal tolerance test. Any individual with a random C-peptide greater
than or equal to 0.1 nmol/l was invited back for a mixed-meal tolerance test
(MMTT). Participants were instructed to fast overnight. At presentation, a
blood glucose level was taken via glucometer, and if the individual’s blood
glucose level was between 5.5 and 8.25 mmol/l, the test was performed.
Otherwise, individuals were given insulin or a snack to reach the appropriate
range before the test was begun (15). Serum samples were assayed for
C-peptide and glucose levels, as detailed above, at time points 0, 30, 60, 90, and
120 min.
Genotyping. DRB1 and DQB1 genotyping was done using linear arrays of
immobilized sequence-speciﬁc oligonucleotides similar to previously de-
scribed methodology, with direct sequencing of DRB1 exon 2 to differentiate
DRB1
*04 subtypes (16).
All Medalists as of January 1, 2008, with a random C-peptide in excess of
0.1 nmol/l (n  50) were genotyped for HNF4A, GCK, TCF1, IPF1, and TCF2
(maturity onset of diabetes in the young [MODY] 1–5, respectively) by Athena
Diagnostics (Worcester, MA).
Histologic studies. Pancreases were obtained through the Juvenile Diabetes
Research Foundation-sponsored Network for Pancreatic Organ Donors with
Diabetes (nPOD) program from 50-year Medalists who consented to postmor-
tem organ donation. The pancreases were procured by the National Disease
Research Interchange and shipped to the nPOD Pathology Core (University of
Florida, Gainesville, FL) where they were breadloafed into up to 20 blocks,
ﬁxed in 10% buffered formalin, and processed routinely for parafﬁn embed-
ding. Sections from blocks spanning the whole pancreas (6–20 blocks per
pancreas, mean 15) were available for eight of the nine; only 2 blocks were
recovered for the remaining pancreases. At the Joslin Diabetes Center,
parafﬁn sections were microwaved for antigen retrieval and immunostained
with guinea pig anti-bovine insulin (1:200, Linco), rabbit anti-bovine glucagon
(1:2000 M. Appel, University of Massachusetts), mouse anti-human Ki67
(1:200, Becton, Dickinson and Company), and rabbit anti-human CD3 (1:50,
Dako) (17). CD3-positive cells in islets were assessed only in regions of the
pancreas without many CD3 cells in the parenchyma. TUNEL (Roche POD
TUNEL kit) was performed on microwaved sections of those pancreases
without extensive autolysis. Amyloid was detected using thioﬂavin S (16).
Images were taken on an Olympus BH2 microscope or in confocal mode with
a Zeiss LSM 410 microscope.
Statistical analysis. All variables were visually inspected and analyzed for
distribution to determine appropriate statistical methods for analysis. A
Wilcoxon rank sum analysis was used for two-way comparisons involving
independent continuous variables, and the Fisher exact test was used to
analyze the relationship of categorical variables. ANOVA and tests for linear
trend were performed using generalized linear models designating group as
categorical or ordinal as appropriate. A paired t test was used to determine if
the differences between fasting and peak values during MMTT were statisti-
cally signiﬁcant. P values  0.05 was considered statistically signiﬁcant. Stata
version 11 (College Station, TX) and SAS version 9.2 (Cary, NC) were used to
perform analyses.
RESULTS
As of September 30, 2008, a total of 411 Medalists had
participated in this study; 47% were male (Table 1). The
average age was 67.2  7.4 years, mean age at diagnosis of
diabetes was 11.0  6.5 years, and mean duration of
diabetes was 56.2  5.8 years. Medalists had a favorable
lipid proﬁle (calculated HDL 1.6  0.58 mmol/l, LDL 2.2 
0.6 mmol/l, total cholesterol 4.2  09 mmol/l, triglycerides
0.9  0.5 mmol/l). Average insulin dose per kilogram was
0.46  0.2 u/kg. The frequency of HLA risk alleles DR3 and
DR4 (0602 excluded) was greater than 93% (Table 1). The
prevalence of participants who were autoantibody positive
was 29.7% (111) for either antigen; 14.9% (55) and 18.4%
(69) for IA2 only or GAD only, respectively (Table 1).
In addition to characterizing basic clinical traits, we
examined family history and the presence of MODY poly-
morphisms. The family histories of both type 1 diabetes
and type 2 diabetes of all patients were reviewed. We
determined that 12.9% of Medalists had at least one
ﬁrst-degree relative with type 1 diabetes, and 29.7% had a
ﬁrst-degree relative with any type of diabetes (Table 1). No
signiﬁcant differences were observed in the frequency of
ﬁrst degree relatives with type 1 diabetes or any type of
diabetes mellitus when random C-peptide levels were
compared (Table 2). Additionally, 50 individuals with
random C-peptide levels in excess of 0.1 nmol/l were
genotyped for risk polymorphisms in MODY genes 1–5 ([1]
HNF4A, [2] GCK, [3] TCF1, [4] IPF1, [5] TCF2). Of those
typed, only 4 were found to have risk polymorphisms
(HNF4A, IPF1 and 2 had TCF1). Only 1 of the 4 identiﬁed
with MODY polymorphisms had a C-peptide level greater
than 0.2 nmol/l. Analyses were done excluding these
individuals and there was no difference in statistical
results.
TABLE 1
Characteristics of Medalist study participants
Male (%) 47.0 (192)
A1C (%) 7.3  1.1
Age (years) 67.2  7.4
Age at diagnosis (years) 11.0  6.5
Duration (years) 56.2  5.8
BMI (kg/m
2) 26.0  5.1
C-peptide (nmol/l) 0.07  0.12
Cholesterol (mmol/l) 4.2  0.9
Calculated HDL (mmol/l) 1.6  0.5
LDL (mmol/l) 2.2  0.6
Triglycerides (mmol/l) 0.9  0.5
Insulin dose (u/kg) 0.46  0.2
Family history of diabetes
Any diabetes 29.7 (122)
Type 1 diabetes 12.9 (53)
DR3* 38.8 (116)
DR4* 52.0 (156)
DR3 or DR4* 93.7 (295)
DR3/4* 39.1 (118)
IA2 or GAD* 29.7 (111)
IA2* 14.9 (56)
GAD* 18.4 (69)
Proliferative diabetic retinopathy* 55 (163)
Microalbuminuria (ACR 7.91)* 13.1 (45)
Neuropathy (MNSI 2)* 60.6 (183)
Cardiovascular disease* 48.3 (160)
Data are means  SD or % (n). *Percentages reﬂect calculations
done on data available. ACR, albumin-to-creatinine ratio; MNSI,
Michigan Neuropathy Screening Instrument.
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Medalists were categorized based on their serum random
C-peptide measures. These categories were derived from
the Diabetes Control and Complications Trial (DCCT)
criteria for examining residual C-peptide production based
on response to MMTT. These categories were as follows:
undetectable, 0.03 nmol/l; minimal, 0.03–0.2 nmol/l; and
sustained, 0.2 nmol/l (17). Our categorization was done
using the patient’s random C-peptide measure. We hypoth-
esize that our means of categorization may underestimate
the degree of insulin production, as random C-peptide
levels are not necessarily at their maximum since produc-
tion was likely not stimulated in most cases. There were
33.0% in the undetectable category, 64.4% with minimal,
and 2.6% with sustained random serum C-peptide levels,
resulting in 67.4% (n  256) with at least detectable
C-peptide levels (Table 2). Analyses indicated a signiﬁcant
difference in glycemic control as measured by glycated
hemoglobin across the DCCT-deﬁned groups of random
serum C-peptide levels, however, did not increase linearly
with C-peptide levels (7.5  1.0%, 7.1  1.1%, and 7.3 
0.7%, respectively, P  0.005). The group with sustained
levels of random C-peptide had a much higher mean of age
at diagnosis (16.2  8.6 years) compared with each of the
other groups (mean of 10.9 years in each of the other
groups, ANOVA P  0.02). MHC HLA risk alleles were also
differentially distributed across these three groups of
random C-peptide (Table 2). The sustained group had the
highest frequency of DR3 risk alleles, whereas the minimal
group (0.03–0.2 nmol/l) had the highest frequency of DR4
risk alleles. Of interest is the higher frequency of the DR3
risk allele among those with sustained random C-peptide
production compared with those with undetectable ran-
dom levels (57.1% vs. 33.6% DR3). The presence of islet cell
antibodies, either IA2 or GAD, was not different across the
three groups; however, the frequency of IA2 autoantibod-
ies was lower than that of GAD in all groups, with none
present in the sustained group (Table 2). As shown in
Table 2, there was no difference across the three groups in
terms of sex, age, duration of disease, A1C, family history
of diabetes, BMI, insulin dose, lipid proﬁle, or prevalence
of microvascular or macrovascular complications.
There were 14 individuals who had signiﬁcantly higher
random C-peptide levels than the majority (in excess of
0.17 nmol/l, representing the top 3.5%) (Fig. 1). On average
these individuals had an older age at diagnosis versus the
rest of the cohort (17.4  7.4 vs. 10.8  6.3 years, P 
0.0008, respectively). Trends that did not reach statistical
signiﬁcance comparing this group with the rest of the
cohort were higher frequency of DR3 or DR4 risk alleles
(100% vs. 93.2%) and lower prevalence of autoantibodies
(20.0% vs. 28.7%).
MMTT. The physiologic characterization of the C-peptide
production in the Medalists was studied through MMTT. A
total of 31 individuals were invited to the Joslin Diabetes
Center for MMTT based on their random C-peptide levels
being greater than 0.1 nmol/l. In addition, 6 nondiabetic
age-matched controls were also studied. Thirteen of the 31
Medalist participants who returned for the MMTT re-
sponded with doubling of C-peptide levels over their level
at time 0 min (Fig. 2). As shown in Fig. 3, the nondiabetic
age-matched controls had fasting levels (mean  SD) of
0.73  0.5 nmol/l and stimulated levels at 60 min of 3.74 
1.1 nmol/l, (P  0.004). The 13 Medalist responders had
fasting C-peptide levels of 0.14  0.2 nmol/l and reached a
maximum of 0.45  0.54 nmol/l at 90 min (P  0.03). In
TABLE 2
Characteristics of Medalist study participants by DCCT categories of residual insulin production
Undetectable 0.03 nmol/l Minimal 0.03–0.2 nmol/l Sustained 0.2 nmol/l P*
N (%) 33.0 (126) 64.4 (246) 2.6 (10)
Male 42.6 (55) 50.2 (123) 52.9 (7) 0.4
A1C (%) 7.5  1.0 7.1  1.1 7.32  0.7 0.005
Age (years) 67.5  8.1 67.0  7.2 71.7  8.3 0.09
Age at diagnosis (years) 10.9  6.8 10.9  6.1 16.2  8.6 0.02
Duration (years) 56.4  6.0 56.1  5.7 55.5  4.1 0.7
BMI (kg/m
2) 26.7  2.8 26.0  4.3 23.8  3.6 0.5
Insulin dose (u/kg) 0.47  0.2 0.5  0.2 0.4  0.2 0.5
Cholesterol (mmol/l) 4.2  0.9 4.2  0.9 4.2  1.1 0.8
Calculated HDL (mmol/l) 1.6  0.9 1.6  0.5 1.7  0.6 0.7
LDL (mmol/l) 2.2  0.6 2.2  0.6 2.2  0.9 0.5
Triglycerides (mmol/l) 0.92  0.5 0.89  0.51 0.98  0.65 0.9
Family history of diabetes†
Any diabetes 27.8 (35) 31.7 (78) 20.0 (2) 0.6
Type 1 diabetes 11.9 (15) 14.2 (35) 10.0 (1) 0.8
DR3† 33.6 (39) 43.8 (84) 57.1 (4) 0.03
DR4† 42.2 (49) 57.7 (112) 42.9 (3) 0.03
DR3/4† 44.8 (52) 36.6 (71) 14.3 (1) 0.14
DR3 or DR4 95.7 (116) 92.2 (177) 100.0 (7) 0.4
IA2 or GAD† 32.8 (40) 27.2 (64) 40.0 (4) 0.7
IA2† 16.3 (20) 13.9 (33) 0 0.3
GAD† 21.1 (26) 16.0 (38) 36.4 (4) 0.1
Proliferative DR† 53.9 (56) 52.7 (97) 36.4 (4) 0.5
Microalbuminuria (ACR 7.91)† 15.1 (18) 10.8 (19) 23.1 (3) 0.3
Neuropathy (MNSI 2)† 60.4 (67) 60.7 (99) 60.0 (6) 0.9
Cardiovascular disease† 46.4 (52) 50.0 (96) 50.0 (5) 0.8
MMTT response 0 (0/3) 14.2 (3/21) 57.1 (4/7) 0.0001
Data are means  SD or % (n). †Percentages reﬂect calculations done on data available. *P values resulted from ANOVA.
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of 0.11  0.1 nmol/l and a maximum level of 0.15  0.2
nmol/l at 90 min (P  0.33) (Fig. 3). Analysis demonstrated
a higher proportion of responders were in the sustained
C-peptide group. It is clear that those diabetic patients
with sustained random levels of C-peptides (57.1%) were
signiﬁcantly more responsive to MMTT, deﬁned as at least
a doubling of baseline fasting measure of C-peptide, than
FIG. 1. Distribution of the ﬁrst 97% of C-peptide levels among 50-year Medalists. Inset shows C-peptide values from all values. These pictures
demonstrate the outlying 3% in excess of 0.17 nmol/l. (A high-quality color representation of this ﬁgure is available in the online issue.)
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C-peptide group showed a signiﬁcantly greater response to
MMTT at 36.4% compared with the minimal group as
established by random C-peptide level 15.0%, (P  0.001).
Histology. Pancreases from 9 Medalists representing all
three DCCT categories of C-peptide production were
recovered after death for pathologic analysis (Table 3). All
were DR3, DR4, or DR3/DR4 positive; and 3 (33%) were
antibody positive to GAD or IA2 autoantibodies. None of
the pancreases studied came from patients who had a
MODY risk polymorphism, and none of these have been
reported before.
Insulin cells were observed in all the pancreases as
scattered single extrainsular cells or small clusters in
some lobes (Table 3). In the seven Medalists who had
onset of diabetes at age 8 or younger, most islets were
atrophic with no insulin staining (Fig. 4A and C), although
there were often also small islets with a few central cells
that did not stain for glucagon. Although these unstained
central cells are hypothesized to be degranulated -cells,
as yet no speciﬁc -cell markers have stained positive.
However, in two of these Medalists, insulin-positive cells
were found within occasional islets.
In the pancreases from the two Medalists (Medalists 8
and 9, Table 3) who had later onset diabetes (23 and 30
years) and responded by doubling their C-peptide during
MMTT, considerably more insulin cells were found, and
these were clearly within islets (Fig. 4D–I). In both, there
were islets depleted of insulin cells, as well as islets with
considerable proportion of insulin cells. Intriguingly, in
Medalist 8 (onset at 23 years), half of the pancreases had
only atrophic islets (Fig. 4C), but in a lobular pattern there
were islets with signiﬁcant insulin cells (Fig. 4D–F) and
even some with amyloid deposits (Fig. 4F). Clinical eval-
uations of Medalist 8 showed her to be positive for DR3
and DR4 and well controlled with an A1C of 6.7%. Two
MMTTs in Medalist 8 conﬁrmed a 360% rise in C-peptide at
90 min.
Turnover of -cells was supported by a few TUNEL
insulin cells in islets or clusters in two of four (50%)
TUNEL-stained pancreases (Fig. 4B) and by Ki67 islet
cells in two other pancreases; only one of which had
insulin Ki67 cells (Fig. 4H).
In three (33%) antibody-negative Medalists, a few CD3
cells were found in insulin islets (Fig. 4I), and in one,
antibody-positive without noticeable insulin cells within
islets, a few islets had a CD3 cell. There were no other CD3
cells in the low magniﬁcation ﬁelds of these pancreases.
DISCUSSION
This study represents the ﬁrst comprehensive analysis of
the clinical characteristics affecting -cell function in a
large cohort of insulin-dependent patients of chronic du-
ration (18). We have correlated these parameters with
postmortem pancreatic pathology of some of the same
patients. The results showed that a majority have the
ability to produce insulin endogenously, as suggested by
random serum C-peptide levels and response to MMTT,
and conﬁrmed by the presence of insulin cells in all nine
available Medalist pancreases, even in those with unde-
tectable random C-peptide values (19). This prevalence of
elevated C-peptide levels (67.4% 0.03 nmol/l) in the
Medalist cohort is the highest among published studies of
type 1 diabetic patients (19,20). The DCCT reported only
11% of patients screened by MMTT, mean duration of 2.3 
0.3 years, had this level of C-peptide (17). Although there
can be differences between random C-peptide levels,
which could be caused by fasting and those resulting from
a MMTT, it is likely that the random serum C-peptides
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results to the null. However, this has not been studied in
individuals with extreme duration of diabetes. Even with
this high percentage of retained insulin production, the
clinical and biochemical characteristics of this population
are consistent with type 1 diabetes: low BMI (26  5.1
kg/m
2), onset of disease at 11  6.5 years, lipid proﬁle of
high HDL (1.6  0.5 mmol/l) and normal LDL (2.2  0.6
mmol/l) and lack of insulin resistance per daily insulin
dose (0.46  0.2 u/kg). Furthermore, this group, geneti-
cally, had a high frequency of HLA diabetes risk alleles
DR3 and/or DR4 (93%) (21,22). Also consistent with type 1
diabetes, 29.5% of Medalists were positive for IA2 or GAD
autoantibodies (23,24). Thus, it is likely that most of the
Medalists studied have autoimmune type 1 diabetes.
The random serum C-peptide levels in the Medalists
spanned a wide range, from undetectable to 1 nmol/l.
Detailed analysis of Medalists’ clinical parameters accord-
ing to their C-peptide levels provided very few clues
regarding the preservation of endogenous insulin produc-
tion, suggesting that multiple factors contribute. Dividing
the cohort into three groups according to C-peptide levels
provided interesting ﬁndings, such as the ﬁnding that
better glycemic control and later age of onset were asso-
ciated with higher C-peptide levels.
A small subset of Medalists with high C-peptide levels
was associated with older age at onset and more -cells.
The pancreases from two of this subgroup (Table 3) had
nearly 10% of normal -cell mass, whereas neither Lohr
and Kloppel (20) nor Meier et al. (11) found a correlation
of later age of onset with residual -cells, although Pipel-
eers and Ling did (10). It is possible that the differential
preservation of insulin producing cells in the Medalists
could have led to their long-term survival.
The MMTT responsiveness of the cohort indicates that
the higher random or fasting C-peptide, the greater pro-
pensity to respond, suggesting some retained -cells have
preserved function. It is interesting to note that in the
MMTT, the fasting and maximum levels of C-peptide
response of the sustained C-peptide group were 10–20%
of those of age-matched nondiabetic controls. For the
nonresponders, the C-peptide levels at fasting and maxi-
mum response were less than 2–3% of the nondiabetic
control. The relative differences in the C-peptide levels
among these groups corresponded to the number of
-cells detected by postmortem morphologic analysis of
the pancreases. Our histologic studies showed that nine of
nine Medalist pancreases, even those (Medalist 1 and 2)
who did not have detectable random C-peptide, had resid-
ual insulin -cells as singlets and small clusters; several
(Table 3) had insulin-positive cells within islets. All of
these would have been classiﬁed as pattern A by the
criteria recently reported (12) since they all were DR3,
DR4, or DR3/4, Caucasian, and had insulin-deﬁcient islets.
The studies of the Medalists provide strong evidence
indicating that residual -cells in type 1 diabetic patients
of chronic duration are in a steady state of cellular
apoptosis and proliferation, even in individuals with dia-
betes of over 50 years duration. Meier et al. (11) reported
both increased apoptosis and evidence of chronic inﬂam-
mation in pancreases from people who had type 1 diabetes
of various durations ranging from 4 to 67 years. Interest-
ingly, insulin -cells were co-labeled with apoptotic and
proliferative markers. In addition, positive CD3 cells were
detected in a few islets in all pancreases studied. Clearly
more data derived from these pancreases and of other
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conclusions.
Because these are human tissues, there is no way to
determine whether the residual -cells survived the initial
autoimmune destruction or formed at some later time.
Although rare -cell replication was seen, in most of the
pancreases the majority of insulin-positive cells were
single cells, often within the ducts. A recent report by
Thorel et al. (25) demonstrated in a murine model that in
-cell–depleted mice, -cells could differentiate into
-cells in mice after prolonged duration of diabetes (i.e.,
10 months). This raises the possibility that the residual
FIG. 4. Histologic ﬁndings in pancreases from nine Medalists. In seven of nine pancreases, there were mainly atrophic islets (A) in which all or
almost all cells were immunostained for glucagon, with occasional small islets that had peripheral glucagon cells with unstained central cells
(asterisks), and rare small clusters or scattered single insulin cells (B); all nine pancreases had these scattered insulin cells. In one
antibody-positive Medalist, some insulin cells were TUNEL-positive (B). In another pancreas (from Medalist 8) (C–F), about half of the
pancreas had only atrophic islets (C), although there were lobes within the body and tail of the pancreas, with most islets with signiﬁcant
proportion of insulin cells (D and E, adjacent sections) and some with amyloid deposits (F) (thioﬂavin S). In another late-onset diabetes
pancreas (Medalist 9; age 30 at onset) (G–I), every islet had at least one insulin cell, and most had 10–20% of normal (G). In this last Medalist
pancreas, rare Ki67insulin cells (arrows indicate Ki67 nuclei, both within the islet and nearby) (H) were found. I: In three pancreases,
CD3 cells were rarely found in insulin islets, whereas no other CD3 cells were found in the microscopic ﬁeld. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
RESIDUAL INSULIN PRODUCTION AFTER 50 YEARS T1DM
2852 DIABETES, VOL. 59, NOVEMBER 2010 diabetes.diabetesjournals.orgC-peptide observed in the Medalists represents a slow
increase of -cell mass/function in this group of patients
with diabetes of extreme duration. It should be noted that
in 5 of the pancreases, the only insulin-positive cells were
singlets or small clusters, and even in the four with
insulin-positive cells within islets, there was no colocaliza-
tion of insulin and glucagon. Thus, the source of residual
-cells in the Medalists is unclear, but it is likely that they
may be derived from multiple sources.
In summary, the study of a large group of insulin-
dependent diabetic patients of extreme duration charac-
terized clinically, biochemically, and histologically has
provided the surprising ﬁnding that residual functional
-cells remain even after 50 years in a majority of these
type 1 diabetic patients. The data presented in this study
clearly support that even under prolonged autoimmune
and metabolic stress, pancreatic -cells can be replen-
ished. Thus, the amelioration of autoimmune stress, to-
gether with stimulus for regeneration of endogenous
-cells, could be a feasible approach to improve endoge-
nous insulin production in a substantial number of pa-
tients with type 1 diabetes.
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